Clinical trials: Glaucoma Therapy
Primary Open Angle Glaucoma, Ocular Hypertension
Laser-1st vs Drops-1st for Glaucoma and Ocular Hypertension
This is a randomized study with two treatment arms: 'initial Selective Laser Trabeculoplasty (SLT) followed by conventional medical therapy as required' ('Laser-1st') and 'medical therapy without laser ('Medicine-1st').
- Trial name
- LIGHT (NCT03395535)
- Testing
- Primary Selective Laser Trabeculoplasty Treatment Pathway, Primary Medical Treatment Pathway
- Where
- United Kingdom
- Volunteers
- 718 people
- Sponsor
- Moorfields Eye Hospital NHS Foundation Trust
Elevated Intraocular Pressure
Acupuncture for Elevated Intraocular Pressure
Glaucoma is the leading cause of irreversible blindness in the world, resulting from progressive axonal destruction of the optic nerve.
- Trial name
- NCT00307918
- Testing
- acupuncture
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Shaare Zedek Medical Center
Primary Open Angle Glaucoma
The Antioxidant Effect of Routine Vascular Therapy for Normal Tension Glaucoma Patients
To quantify oxidative stress in circulating leukocytes of normal tension glaucoma patients, prior to and one month after routine vascular therapy.
- Trial name
- NCT00465348
- Volunteers
- healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Glaucoma, Open Angle
Study of Medical Treatment of Low-Pressure (Normal Tension) Glaucoma
Low-pressure (normal tension) glaucoma is a type of open-angle glaucoma resulting in damage to the optic nerve and abnormalities of the visual field.
- Trial name
- NCT00317577
- Testing
- brimonidine, timolol
- Where
- 12 sites in United States
- Volunteers
- 160 people
- Sponsor
- Chicago Center for Vision Research
Glaucoma, Open-angle
Non Interventional Study With Primary Open Angle Glaucoma and/or Ocular Hypertension Patients Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy.
This study is designed to evaluate the safety and tolerability of Xalacom in patients with primary glaucoma
- Trial name
- NCT00801437
- Testing
- Xalacom
- Where
- 39 sites in Slovakia
- Volunteers
- 457 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Childhood Glaucoma
Efficacy and Safety of Topically Applied Medical Therapy for the Treatment of Pediatric Glaucoma
Objectives: The study will assess the ocular hypotensive effect of latanoprost and dorzolamide in a selected sample of patients affected by primary Pediatric Glaucoma (PG), refractory to surgical procedures.
- Trial name
- NCT01527682
- Testing
- Latanoprost, Dorzolamide
- Where
- 2 sites in Italy
- Volunteers
- 37 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Open Angle Glaucoma, Ocular Hypertension
A Investigator Masked Parallel Comparison of Tolerability of Combigan and Cosopt
The objective of this research study is to compare the tolerability and effectiveness of Combigan(brimonidine tartrate/timolol maleate) and Cosopt (dorzolamide hydrochloride)in the treatment of open angle glaucoma or ocular…
- Trial name
- CICOM1010 (NCT00621335)
- Where
- Canada
- Volunteers
- 64 people
- Sponsor
- DBYAN Medicine Professional Corporation
Patient Noncompliance, Health Literacy
Impact of Health Literacy and Other Factors on Glaucoma Patient Adherence in South India
The purpose of this study is to determine how health literacy impacts glaucoma patient adherence (as measured by following up with the doctor) in Tamil Nadu, India.
- Conditions
- Patient Noncompliance, Health Literacy, Glaucoma
- Trial name
- NCT00694876
- Where
- India
- Volunteers
- 250 people
- Sponsor
- Robin, Alan L., M.D.
Retinal Disease, Macular Degeneration
Stem Cell Ophthalmology Treatment Study
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease. http://mdstemcells.com/scots-ii/
- Conditions
- Retinal Disease, Macular Degeneration, Hereditary Retinal Dystrophy, Optic Nerve Disease
- Trial name
- SCOTS (NCT01920867)
- Testing
- RB (Retrobulbar), ST (Subtenon), IV (Intravenous)
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- MD Stem Cells
Medication Adherence, Glaucoma
A Universal Eye Drop Adherence Monitor to Measure and Improve Adherence to Ocular Medications
Glaucoma is the second leading cause of visual impairment worldwide. Eye drop medications reduce vision loss from glaucoma by at least 60%, but eye drops must be taken every day to be effective.
- Trial name
- NCT03506568
- Testing
- Devers Drop Device (D3) app
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Universal Adherence LLC
Glaucoma
Efficacy of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination) From Prior Therapy
The purpose of this study is to assess efficacy and tolerability of changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-free) from prior Xalacom® or Ganfort® fixed combination pharmacotherapy in patients with open-angle…
- Trial name
- NCT01514721
- Testing
- Travoprost/Timolol Maleate BAK-Free Fixed Combination
- Where
- Brazil
- Volunteers
- 37 people
- Sponsor
- Alcon Research
Glaucoma
Electrical Stimulation of the Optic Nerve in Patients With Glaucoma.
The goal of this observational study is to evaluate electrical stimulation of the optic nerve with the Eyetronic Nextwave System device as a possible treatment for glaucoma.
- Trial name
- NCT06693882
- Testing
- EYETRONIC Nextwave System
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Glaucoma Center of San Francisco
Primary Open Angle Glaucoma
CRISPR/Cas9 Instantaneous Gene Editing Therapy to Intraocular Hypertensive POAG With MYOC Mutation
This study is intented to evaluate the safety, tolerability and preliminary efficacy of CRISPR/Cas9 Instantaneous Gene Editing Therapy (BD113 virus-like particle, also BD113vLVP) in patients with primary open-angle glaucoma…
- Trial name
- NCT06465537
- Testing
- BD113vVLP
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai BDgene Co., Ltd.
Primary Angle Closure Glaucoma, Primary Angle Closure
Hydrus Microstent and Lens Extraction for the Treatment of Primary Angle-Closure Glaucoma
This study is a prospective evaluation of the Hydrus Microstent for the treatment of Primary Angle Closure (PAC) and Primary Angle Closure Glaucoma (PACG) with adjunctive cataract.
- Trial name
- NCT04622605
- Testing
- Trabecular bypass and Schlemm's canal stent
- Where
- Philippines
- Volunteers
- 31 people
- Sponsor
- Asian Eye Institute
Primary Open Angle Glaucoma, Ocular Hypertension
Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension
Aim: To demonstrate the non-inferiority of the PRO-067 ophthalmic solution manufactured by Laboratorios Sophia S.A. de C.V. versus GAAP Ofteno® ophthalmic solution like hypotensive therapy in subjects with primary open angle…
- Trial name
- COMPLIANCE (NCT02801617)
- Testing
- PRO-067, GAAP Ofteno®
- Where
- Mexico
- Volunteers
- 116 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Primary Open Angle Glaucoma
Multimodal Morpho-functional Study in Glaucoma Patients-Citicoline Oral Solution
A prospective, multicentre, randomized, blinded, masked study that involves the enrollment of 60 patients affected by open angle glaucoma (OAG).
- Trial name
- NCT05315206
- Testing
- Citicoline
- Where
- 2 sites in Italy
- Volunteers
- 29 people
- Sponsor
- Fondazione G.B. Bietti, IRCCS
Glaucoma, Open-Angle, Ocular Hypertension
Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
This study will evaluate the safety and efficacy of Triple Combination Therapy compared with Fixed Combination brimonidine tartrate/timolol ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01217606
- Testing
- bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy), Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution
- Where
- Brazil
- Volunteers
- 185 people
- Sponsor
- Allergan
The Objective of the Study is to Prospectively Compare the Success Rate of ab Externo and Interno Implantation
A Prospective, Single Surgeon, Randomized Control Study Comparing ab Interno XEN Gel Microstent Implantation vs Closed Conjunctiva ab Externo Implantation Performed at the Slit Lamp for the Treatment of Uncontrolled Glaucoma
The objective of the study is to prospectively compare the success rate of ab externo implantation and outcome measures of glaucoma filtering surgery namely IOP (intraocular pressure), number of glaucoma medications, adjunct…
- Trial name
- NCT04943185
- Testing
- XEN gel microstent implantation
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Institut de l'oeil des Laurentides
Open-angle Glaucoma, Ocular Hypertension
A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension
The objective of this study is to investigate whether the IOP (intraocular pressure) -lowering effect of DE-111A (preservative-free fixed dose combination of 0.0015% tafluprost and 0.5% timolol eye drops, administered one drop a…
- Trial name
- NCT03822559
- Testing
- A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL, A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mL
- Where
- 2 sites in China
- Volunteers
- 219 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Glaucoma, Open-Angle, Ocular Hypertension
A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
An observational study comparing changing from an IOP-lowering treatment to a bimatoprost-containing IOP treatment in primary open-angle glaucoma (POAG) or ocular hypertension (OHT).
- Trial name
- NCT01646151
- Testing
- Bimatoprost
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 2,580 people
- Sponsor
- Allergan